Ferring Favorite To Get First Approval For Microbiota-Based Therapy
If all goes well, 2020 could see the Swiss firm's Rebiotix subsidiary get a green light from the FDA for its recurrent Clostridioides difficile fecal product.
If all goes well, 2020 could see the Swiss firm's Rebiotix subsidiary get a green light from the FDA for its recurrent Clostridioides difficile fecal product.